|
 |
Volume 4, Number 3 (March 2007) | |||||
Letter from the Editor |
|||||
113 |
On two fronts in cancer care: politics and treatment The West Clinic, Memphis, TN At Community Oncology’s second annual conference, we heard in no uncertain terms that reimbursement in medical oncology has reached the breaking point. But our efforts at grass-roots advocacy are paying off. The other major meeting theme: the rich and growing number of treatment options for cancer patients. In this issue, we focus on the benefits and side effects of panitumumab for colorectal cancer, HER1/EGFR inhibitors, and follicular rash, and the latest therapies for multiple myeloma and toxicities of thalidomide and lenalidomide.
|
||||
Community Translations |
|||||
121 |
Panitumumab in metastatic colorectal cancer Panitumumab, the first fully human monoclonal antibody for chemotherapy-refractory disease, also shows promise in first-line treatment. It is a valuable weapon in the fight against colorectal cancer, which continues to be a major public health problem. The third most common cancer in both men and women, colorectal cancer is already metastatic at diagnosis in 15% to 25% of patients. Up to 50% of patients will eventually develop metastatic disease. Anti-EGFR agents such as panitumumab may contribute significantly to making this disease a manageable chronic condition. Our article summarizes the current research on panitumumab and offers three distinct perspectives. | ||||
FROM THE COMMUNITY ONCOLOGIST'S PERSPECTIVE Palo Verde Hematology/Oncology, Glendale, AZ | |||||
FROM THE NURSE'S PERSPECTIVE Palo Verde Hematology/Oncology, Glendale, AZ | |||||
FROM THE ADMINISTRATOR'S PERSPECTIVE Palo Verde Hematology/Oncology, Glendale, AZ
| |||||
Managing Side Effects |
|||||
129 |
Epoetin alfa for chemotherapy-induced anemia: assessment of two equivalent dosing regimens Pennsylvania Oncology Hematology Associates, Philadelphia, PA, and Department of Medicine, Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA This review article summarizes the clinical data from key studies of each dosage regimen of epoetin alfa for anemia, a frequent complication in patients with cancer receiving myelosuppresive chemotherapy. If left untreated, anemia can have serious adverse sequelae. According to the most recently updated clinical practice guidelines of the National Comprehensive Cancer Network, treatment with erythropoietic therapy should be considered for patients whose hemoglobin concentration is < 11 g/dL.
|
||||
Controversies in Patient Care |
|||||
151 |
Patients seeking second medical hematology/oncology opinions in the United States: a report of their demographics and disease processes Mayo Clinic, Scottsdale, AZ The seeking and rendering of second opinions are common occurrences in the routine delivery of medical care in the United States. Virtually all subspecialties of medicine offer second opinions to patients seeking them. For patients and the medical community alike, however, the benefit associated with obtaining a second opinion remains unclear.
|
||||
Nursing Management |
|||||
157 |
Managing follicular rash related to chemotherapy and monoclonal antibodies Alvin & Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, MD; Alvin & Lois Lapidus Cancer Institute at Northwest Hospital Center, Randallstown, MD; and Sinai Hospital, Baltimore, MD The authors have developed several innovative ways to treat follicular rash. Although these methods are not research based-antidotes, their demonstrated value merits dissemination. Two case studies are included, both written by patients, one of whom is also a physician, to provide insight into how this problem affects people and the importance of recognizing and treating follicular rash early in its course. A series of management steps is offered.
|
||||
Community Oncology Meeting News |
|||||
119 |
Community oncologists meet in Capital
| ||||
Cases in Community Oncology |
|||||
137 |
Advances in the treatment of multiple myeloma US Oncology, Cancer Centers of Florida, Orlando
| ||||
Brief Communications |
|||||
144 |
Synchronous pancreatic cancer and mantle cell lymphoma: a case report University Hospitals Health Care System, Cleveland, OH
| ||||
Adverse Events Alert |
|||||
147 |
Thalidomide- and lenalidomide-associated thromboembolism Northwestern University, Chicago, IL
| ||||
Meetings Highlights |
|||||
FROM THE 29TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM | |||||
164 |
Breast cancer preventive effect of tamoxifen persists after discontinuation of therapy
| ||||
165 |
Balance of efficacy and toxicity varies with trastuzumab for early breast cancer
| ||||
166 |
Lapatinib-paclitaxel combo shows promise in IBC
| ||||
166 |
Study supports weekly nab-paclitaxel for MBC
| ||||
167 |
Treatment-induced amenorrhea improves prognosis of early, ER/PR-positive breast cancer
| ||||
168 |
Reduced-fat diet lowers risk of relapse in early-stage breast cancer
| ||||
Washington Update |
|||||
171 |
Medicare recovery audit program going national
| ||||
© 2007 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
|||||
46 kb